# Effect of Tafoxiparin on Cervical Ripening and Induction of Labor in Term Pregnant Women With an Unripe Cervix

> **NCT04000438** · PHASE2 · COMPLETED · sponsor: **Dilafor AB** · enrollment: 365 (actual)

## Conditions studied

- Labor Onset and Length Abnormalities

## Interventions

- **DRUG:** DF01
- **DRUG:** PL1

## Key facts

- **NCT ID:** NCT04000438
- **Lead sponsor:** Dilafor AB
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-06-21
- **Primary completion:** 2023-02-14
- **Final completion:** 2023-03-30
- **Target enrollment:** 365 (ACTUAL)
- **Last updated:** 2025-05-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04000438

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04000438, "Effect of Tafoxiparin on Cervical Ripening and Induction of Labor in Term Pregnant Women With an Unripe Cervix". Retrieved via AI Analytics 2026-06-15 from https://api.ai-analytics.org/clinical/NCT04000438. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*